Hydrogen sulfide alleviates hypothyroidism-induced myocardial fibrosis in rats through stimulating autophagy and inhibiting TGF-β1/Smad2 pathway
Xiong Song1,#, Liangui Nie1,#, Junrong Long2, Junxiong Zhao1, Xing Liu1, Liuyang Wang1, Da Liu1, Sen Wang1, Shengquan Liu1,*, and Jun Yang1,*
1Department of Cardiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, 2Department of Cardiology, The People's Hospital of Shuangfeng County, Loudi, Hunan 417700, China
Author contributions: Conceived and designed the experiments: X.S., L.N., J.L., J.Z., X.L., L.W., D.L., S.W., S.L., and J.Y. All authors read and approved the final manuscript.
Received: August 23, 2021; Revised: December 28, 2021; Accepted: January 5, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hypothyroidism alone can lead to myocardial fibrosis and result in heart failure, but traditional hormone replacement therapy does not improve the fibrotic situation. Hydrogen sulfide (H2S), a new gas signaling molecule, possesses anti-inflammatory, antioxidant, and anti-fibrotic capabilities. Whether H2S could improve hypothyroidism-induced myocardial fibrosis are not yet studied. In our study, H2S could decrease collagen deposition in the myocardial tissue of rats caused by hypothyroidism. Furthermore, in hypothyroidism-induced rats, we found that H2S could enhance cystathionine-gamma-lyase (CSE), not cystathionine β-synthase (CBS), protein expressions. Finally, we noticed that H2S could elevate autophagy levels and inhibit the transforming growth factor-β1 (TGF-β1) signal transduction pathway. In conclusion, our experiments not only suggest that H2S could alleviate hypothyroidism-induced myocardial fibrosis by activating autophagy and suppressing TGF-β1/SMAD family member 2 (Smad 2) signal transduction pathway, but also show that it can be used as a complementary treatment to conventional hormone therapy.
Hypothyroidism alone can damage cardiac contractility, lead to myocardial fibrosis, and eventually to heart failure [1,2]. Especially, myocardial fibrosis represents a poor prognosis . When myocardial fibrosis occurs, not only do myocardial fibroblasts secrete much extracellular matrix due to overproduction of collagen, making the heart muscle stiffer and exacerbating the prognosis of many heart diseases, but the fibrotic heart tissue causes electrical and structural changes that predispose patients to arrhythmias, heart failure and ischemia . Traditional long-term thyroid replacement therapy can quickly restore hormone levels in the body and gradually improve cardiac function, but not fibrotic situation . In our previous research, H2S, a newly found functional gas, could ameliorate myocardial fibrosis in diabetic rats . However, Whether H2S could treat myocardial fibrosis induced by hypothyroidism remains obscure.
Autophagy is a common physiological process that maintains the cell metabolic homeostasis in response to various cell stressors . Moreover, hypothyroidism is characterized by enhanced thyrotropic stimulating hormone (TSH) level and reduced free thyroxine 4 (FT4) in serum, and TSH stimulation could suppress autophagy in primary mouse chondrocytes (PMCs) . In addition, transforming growth factor-β1 (TGF-β1), a kind of unreplaceable transcription factor, takes a leading role in the occurrence and progression of myocardial fibrosis. SMAD family member 2 (Smad2), a receptor of TGF-β1, is the main molecule in the signal transduction pathway that mediates myocardial fibrosis [9,10]. However, whether autophagy and TGF-β1 signaling pathway are involved in hypothyroidism-induced myocardial fibrosis remain unknown.
In this study, we aimed at providing an effective drug component for treating hypothyroidism-induced myocardial fibrosis as a complement to thyroid replacement therapy. Furthermore, we explored the intrinsic mechanism for providing promising threptic targets.
We purchased eight-week-old male Sprague–Dawley (SD) rats from Changsha Slack Animal Experiment Center. After adaptive feeding for one week in a specific pathogen-free environment, we divided them into four groups: Control group, Hypothyroidism group (PTU group), PTU+H2S group (H2S intervention group), and H2S group (H2S control group). In the following 6 weeks, the rats in PTU group and PTU+H2S group were given PTU (propylthiouracil; Meilun Biological Company, Dalian, China) by gavage at a dose of 20 mg/100 g [1,5], while the other rats were treated with normal drinking water. In the following 4 weeks, the rats in PTU+H2S group and H2S group were intraperitoneally injected with NaHS (Sigma Aldrich, St. Louis, MO, USA) at the dose of 56 µmol/kg/d , while the other rats were treated with same amount of saline. Finally, the rats were sacrificed under chloral hydrate anesthesia (350 mg/kg). All protocol of animal work was authorized by the Animal Ethics Committee of the University of South China. In addition, all the animal experiments conformed to the Institutional and International ethical guidelines.
Enzyme-linked immunosorbent assay (ELISA)
We detected the concentrations of FT4 and TSH from rat serum using ELISA method according the protocol (Beyotime, Shanghai, China). After centrifuging the serum, the supernatant serum was taken to be added into 96-well plates (100 µl per well), shaken and incubated at 37°C for 2 h. Then 100 µl biotin-labelled antibody working solution was added into each well, incubated for 1 h, washed, shaken dry. Next, 100 µl horseradish peroxidase-labelled affinity solution was added, incubated again for 1 h, washed, the substrate solution was added sequentially, incubated for 30 min away from light. Finally, the reaction was terminated sequentially by adding the termination solution, and the absorbance of each well was measured at 450 nm within 5 min.
All the data about the left ventricular function among all the rats were recorded by Visualsonics Vevo 2100 small animal echocardiography (Bio-Rad Laboratories, Hercules, CA, USA). Left ventricular end-systolic diameter (LVES), left ventricular end-diastolic diameter (LVED), left ventricular posterior wall thickness (LVPW), and interventricular septal thickness (IVSD) were recorded and left ventricular fractional shortening (LVFS) was calculated.
We operated Masson staining to observe the collagen deposition in myocardial interstitial tissue. The ventricular muscle specimens were fixed with 4% paraformaldehyde, subjected for ethanol gradient dehydration, and then processed in xylene transparency, paraffin embedding, sectioning (4-µm-thick sections), dewaxing and hydrating, hematoxylin dyeing, decolorizing, ponceau acid fuchsin solution dyeing, and differentiating in 1% phosphomolybdic acid aqueous solution. After observed under a light microscope, they were counter-stained with aniline blue dye solution, soaked in 1% glacial acetic acid, dehydrated in alcohol, and cleared in xylene. Finally, they were observed under a light microscope (Motic, Xiamen, China), after sealing.
We extracted myocardial protein from left ventricular tissue in the ice-cold grinding bowl, and quantified them according to BCA protein assay kit protocol (Beyotime). Then 20 µg lysates were run on 10% SDS-PAGE gel and transferred to 0.45 µm PVDF membranes (Millipore, Billerica, MA, USA). Subsequently, blocked in 5% nonfat milk for one hour, the bands were then incubated with the specific first antibodies (anti-CSE, 1:1,000; anti-CBS, 1:1,000; anti-GAPDH, 1:1,000, anti-TIMP2, 1:1,000; anti-MMP13, 1:1,000; anti-Smad2, 1:500; anti-TGF-β1, 1:1,000; anti-p-Smad2, 1:1,000; anti-Atg4, 1:1,000; anti-Atg5, 1:1,000; anti-Beclin1 1:1,000; anti-P62, 1:1,000; anti LC3II/I, 1:1,000) at 4°C overnight. Then they were bound with horseradish peroxidase-conjugated (HRP) secondary antibodies (1:5,000) for one hour at room temperature. Finally, the bands were visualized by adding with enhanced chemiluminescence complied with the manufacturer’s instruction (Beyotime) and detected by using a Molecular Imager VersaDoc MP 5000 system (Bio-Rad Laboratories), analyzed by ImageJ software.
Data are presented as mean ± SD. Differences among multiple groups were performed by one-way ANOVA. Differences between two groups were compared using post-hoc least significant difference (LSD) test. SPSS 25.0 software (IBM Co., Armonk, NY, USA) was used for statistical analysis. p < 0.05 was considered statistically significant.
Before sacrificing all the rats, FT4 and TSH samples from the tail vein blood of each group of rats were detected. As shown in Table 1, as expected, FT4 levels were significantly reduced and TSH levels were obviously increased in PTU group (p < 0.05). However, compared to PTU group, FT4 and TSH levels were not significantly changed in PTU+H2S group. These data suggest that the animal models were successfully created but H2S is not able to restore the balance of thyroid hormone levels in such a short time.
Table 1 . Detection of the concentration of FT4 and TSH among four groups.
Values are expressed as mean ± SD. FT4, free thyroxine 4; TSH, thyrotropic stimulating hormone; PTU, propylthiouracil; H2S, hydrogen sulfide. *p < 0.05 vs. Control group.
H2S can improve the myocardial fibrosis of hypothyroidism rats
We performed Masson staining method to observe the collagen deposition in hypothyroidism-induced rats heart tissue. As shown in Fig. 1A, B, the collagen deposition content (blue part) in heart tissue of rats in PTU group is much larger than that in Control group (p < 0.05). Compared with that in PTU+H2S group, the collagen deposition content (blue part) is much smaller (p < 0.05). These results indicate that H2S is not able to actually alleviate the hypothyroidism-induced cardiac hypertrophy in heart tissue level.
Figure 1.Hydrogen sulfide (H2S) could ameliorate hypothyroidism-induced myocardial fibrosis and dysfunction.
(A, B) Results of Masson staining in myocardial tissue among four groups. The red part represents the arrangement of myocardial tissue, and the blue part represents myocardial collagen deposition (A: magnification ×40). (C) Cardiac function was evaluated by M-mode echocardiography (a: Control group, b: PTU group, c: PTU+H2S group, d: H2S group). PTU, propylthiouracil. *p < 0.05 compared with Control group; #p < 0.05 compared with PTU group.
H2S can improve the cardiac function of hypothyroidism rats
In order to observe cardiac function among all the rats, we assessed the values of LVED, LVES, LVPW, and IVSD were measured and LVFS (%). As shown in Table 2 and Fig. 1C. The results from M-mode echocardiography showed that, compared to PTU group, PTU+H2S group had decreased values of LVED and LVES (p < 0.05) and increased values of LVFS (p < 0.05). While the values of LVPW and IVSD did not change differently between the two groups. These data suggest that H2S can improve the hypothyroidism-induced cardiac dysfunction.
Table 2 . Contrast of echocardiographic parameters among four groups.
Values are expressed as mean ± SD. LVES, left ventricular end-systolic diameter; LVED, left ventricular end-diastolic diameter; LVPW, left ventricular posterior wall thickness; IVSD, interventricular septal thickness; LVFS, left ventricular fractional shortening; PTU, propylthiouracil; H2S, hydrogen sulfide. *p < 0.05 vs. Control group; #p < 0.05 vs. PTU group.
H2S has no significant effect on cardiac hypertrophy in hypothyroidism rats
In order to detect the effect of H2S on cardiac hypertrophy in hypothyroidism-induced rats. heart weight (HW), body weight (BW) and of all the rats were obtained and values of HW/BW were calculated. As shown in Table 3, the mean value of HW/BW in PTU+H2S group was not evidently superior to that in PTU group (p < 0.05). These results indicate that H2S is not able to actually alleviate the hypothyroidism-induced cardiac hypertrophy in heart tissue level.
Table 3 . The values of heart weight (HW), body weight (BW) and ratio of HW and BW among four groups.
Values are expressed as mean ± SD. PTU, propylthiouracil; H2S, hydrogen sulfide. *p < 0.05 vs. Control group.
H2S can upregulate CSE, not CBS, protein expression level in hypothyroidism-induced myocardial fibrosis tissue in rats
As shown in Fig. 2A–C, We performed Western blot to view cystathionine-gamma-lyase (CSE) and cystathionine β-synthase (CBS) protein expressions. Compare to Control group, both of them were decreased in PTU group (p < 0.05). However, in PTU+H2S group, CSE, not CBS, protein expression level was upregulated compared with PTU group (p < 0.05). These data indicate that H2S can raise CSE expression in hypothyroidism-induced rat heart.
Figure 2.Hydrogen sulfide (H2S) can enhance CSE protein expression and TIMP2/MMP13 protein expression ratio.
(A–C) CSE and CBS protein expressions among four groups. (D, E) MMP13 and TIMP2 protein expressions among four groups. CSE, cystathionine-gamma-lyase; CBS, cystathionine β-synthase; MMP13, matrix metalloproteinase 13; TIMP2, tissue inhibitor of metalloproteinase 2; PTU, propylthiouracil. *p < 0.05 compared with Control group; #p < 0.05 compared with PTU group.
H2S can upregulate TIMP2/MMP13 protein expression ratio in hypothyroidism-induced myocardial fibrosis tissue
We employed Western blot to observe MMP13 and TIMP2 expressions in the heart tissue of rats in each group. As shown in Fig. 2D, E, MMP13 protein expression was upregulated (p < 0.05) and TIMP2 was downregulated (p < 0.05) in PTU group, while MMP13 was decreased (p < 0.05) and TIMP2 was increased (p < 0.05) in PTU+H2S group. These data suggest that H2S can up-regulate TIMP2/MMP13 ratio in fibrotic heart tissue of hypothyroidism-induced rats.
H2S can improve hypothyroidism-induced myocardial fibrosis by suppressing TGF-β1/Smad2 signal transduction pathway
We performed Western blot to determine TGF-β1, Smad2, and p-Smad2 expressions. As shown in Fig. 3A–C, these proteins expressions were upregulated in PTU group (p < 0.05) and downregulated in PTU+H2S group (p < 0.05). These data imply that inhibition of TGF-β1/Smad2 pathway is devoted to the process of H2S mitigating hypothyroidism-caused myocardial fibrosis.
Figure 3.Hydrogen sulfide (H2S) can inactivate the TGF-β1/Smad2 pathway activated by PTU and upregulate the autophagy downregulated by PTU.
(A–C) TGF-β1 and Smad2, p-Smad2 protein expressions among four groups. (D–F) Atg4, Atg5, Beclin1, LC3II/I and P62 protein expressions among four groups. TGF-β1, transforming growth factor-β1; Smad2, SMAD family member 2; PTU, propylthiouracil. *p < 0.05 compared with Control group; #p < 0.05 compared with PTU group.
H2S can improve hypothyroidism-induced myocardial fibrosis by raising autophagy
We used Western blot to detect autophagy-related proteins expressions. As shown in Fig. 3D–F, Atg4, Atg5, Beclin1, LC3II/I expressions were reduced (p < 0.05) and P62 increased (p < 0.05) in PTU group, while Atg4, Atg5, Beclin1, LC3II/I expressions were upregulated (p < 0.05) and P62 downregulated (p < 0.05) in PTU+H2S group (p < 0.05). These data suggest that H2S can activate autophagy in hypothyroidism-induced fibrotic myocardial tissue in rats.
It has been reported that hypothyroidism is highly related to various cardiovascular diseases, such as atrial fibrillation, myocardial fibrosis and heart failure [5,12,13]. However, classic long-term thyroid replacement therapy owns little ability to improve cardiac fibrotic situation . H2S has been proven to possess the effect of anti-myocardial fibrosis after acute myocardial infarction in our previous experiments, and one of the main mechanisms is through upregulating TIMP2/MMP13 ratio . So as to alleviate excessive damage of myocardial fibrous structure caused by overactivation of MMPs proteins . Similar changes were found in our experiments, H2S alleviate the degree of hypothyroidism-induced myocardial fibrosis in SD rats, increase the TIMP2/MMP13 ratio and improve cardiac function. As well, H2S could relieve myocardial fibrosis, which usually comes from chronic inflammatory process, via exerting its anti-inflammatory and antioxidant effects [16,17]. Therefore, H2S could be a supplement for traditional thyroid replacement therapy to relieve hypothyroidism-induced myocardial fibrosis.
To further verify whether the improving effect is related to the endogenous H2S producing ability in heart tissue. In our experiment, we found that CSE protein expression level in heart tissue was recovered in the process of H2S alleviating hypothyroidism-induced myocardial fibrosis. Although, it was reported that knockdown of CSE gene did not significantly aggravate the chronic fibrotic response to myocardial infarction in mice , we assume the discrepancy is the results of the differences of animal modeling method and species. However, the fibrotic degree was alleviated after administration of NaHS, it was credited with decreasing inflammatory response by upregulating CSE expression . Besides, we assumed that the CBS protein expression level was not altered in this improving process because CBS is not the main H2S producing enzyme in heart tissue, but brain tissue . Hence, we can propose that impaired endogenous H2S generating ability was involved in the myocardial fibrosis process and restoration of this ability in heart tissue is involved in the process of exogenous H2S alleviating the myocardial fibrosis.
It has been reported that TSH stimulation could downregulate autophagy flux in PMCs . Similarly, we found hypothyroidism could suppress autophagy in rat heart tissue in this experiment and H2S could ameliorate this pathological process. Also, activating autophagy could clear damaged organelles and extra collagen deposition to maintain cellular homeostasis so that severity of myocardial fibrosis and cardiac hypertrophy got alleviated [16,21,22]. H2S acts like a “switcher” in the autophagy process to regulates structure and function of myocardium in myocardial diseases . On the other hand, some researchers showed that inhibition of excessive autophagy could improve cardiac fibrosis [24,25]. In these autophagic indicators, Beclin1 represents the initial stage of autophagy and interacts with multiple proteins in different stages [26,27]. Atg4 represents the autophagosome formation process , Atg5 represents the autophagosome elongation and closure , P62 acts as a cargo protein, loaded with the ubiquitylated target proteins, ready for delivery to lysosome degradation , which make it represent a biomarker of fusion and digestion in the autophagy process. As for LC3II/I, the transition from LC3I to LC3II, an autophagic membrane-bound form of LC3, plays a role the entire autophagic process [30,31]. Although the identification of autophagy is difficult to be defined in the field of myocardial fibrosis research , activating autophagy by H2S is an adaptive cellular energy metabolic processes in hypothyroidism-induced myocardial fibrosis. And the specific molecular regulating mechanism is needed to be further explored.
TGF-β1 signaling pathway, one of the commonly recognized key regulators on myocardial fibrosis, plays an essential role in the pathogenesis of myocardial fibrosiss [33-35]. It has been reported that H2S could act as an antioxidant against reactive oxygen species (ROS) in spontaneously hypertensive rats (SHR) , yet ROS biogenesis contributes to TGF-β1-mediated pro-fibrotic response . In other experiments, administration of H2S could inhibit ROS production to mitigate TGF-β1 expression in injured renal caused by angiotensin converting enzyme (ACE) . Addition of NaHS could ameliorate TGF-β expression through reducing ROS level to prevent lipopolysaccharide (LPS)-induced anxiety-like behavior deficits . What is more, treatment of NaHS was able to decrease TGF-β1 expression level by repressing ROS generation so that hyperglycemia-mediated injured kidney got eased . Thus, it could be speculated that H2S can inhibit TGF-β1 signal via the reduction of ROS. On the other hand, TGF-β1/Smad2 itself is a signaling pathway whose activation mediates a series of pathophysiological responses. Moreover, its stimulation could upregulate MMP2/9 level to aggravate myocardial fibrosis . Thus it can be inferred that TGF-β1/Smad2 pathway activation could mediate down-regulation of TIMP2/MMP13. In our experiments, H2S could inhibit TGF-β1/Smad2 transduction signal pathway in PTU-induced myocardial fibrosis. Therefore, we can speculate that TGT-β1/Smad2 pathway is a potential therapeutic target and further suggest that H2S is a potential drug component for myocardial fibrosis.
In conclusion, our results not only demonstrate that H2S could relieve hypothyroidism-induced myocardial fibrosis by upregulating autophagy and inhibiting TGF-β1/Smad2 pathway, but also indicate that targeting TGF-β1/Smad2 pathway might be an effective strategy for treatment of myocardial fibrosis. Moreover, H2S could be a complement treatment for traditional hormone replacement therapy. To verify the authenticity of this inference, in our further experiments, further observe on the myocardial fibrosis and cardiac function of H2S on the basis of traditional hormone replacement therapy in different periods will be employed, and autophagy inhibitor and TGF-β1 Pathway activators will be adopted to verify its mechanism. When a mature H2S drug formulation is developed, we will apply for a clinical trial of H2S in patients with hypothyroidism.
This work was supported by the Scientific Research Fund Project of Hunan Provincial Health Commission (Grant No 20201913), the Natural Science Foundation of Hunan Province (Grant No 2020JJ5505) and National Natural Science Foundation of China (Grant No 81870230).
Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005;112:3122-3130.
Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J. 2017;13:55-59.
Bano A, Chaker L, Muka T, Mattace-Raso FUS, Bally L, Franco OH, Peeters RP, Razvi S. Thyroid function and the risk of fibrosis of the liver, heart, and lung in humans: a systematic review and meta-analysis. Thyroid. 2020;30:806-820.
Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S. Myocardial fibrosis. Tidsskr Nor Laegeforen. doi: 10.4045/tidsskr.17.1027.
Hajje G, Saliba Y, Itani T, Moubarak M, Aftimos G, Farès N. Hypothyroidism and its rapid correction alter cardiac remodeling. PLoS One. 2014;9:e109753.
Liu M, Li Y, Liang B, Li Z, Jiang Z, Chu C, Yang J. Hydrogen sulfide attenuates myocardial fibrosis in diabetic rats through the JAK/STAT signaling pathway. Int J Mol Med. 2018;41:1867-1876.
Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069-1075.
Xin W, Yu Y, Ma Y, Gao Y, Xu Y, Chen L, Wan Q. Thyroid-stimulating hormone stimulation downregulates autophagy and promotes apoptosis in chondrocytes. Endocr J. 2017;64:749-757.
Chen T, Li J, Liu J, Li N, Wang S, Liu H, Zeng M, Zhang Y, Bu P. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway. Am J Physiol Heart Circ Physiol. 2015;308:H424-H434.
Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee SJ, Karch J, Molkentin JD. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127:3770-3783.
Xiao T, Luo J, Wu Z, Li F, Zeng O, Yang J. Effects of hydrogen sulfide on myocardial fibrosis and PI3K/AKT1-regulated autophagy in diabetic rats. Mol Med Rep. 2016;13:1765-1773.
Moon S, Kim MJ, Yu JM, Yoo HJ, Park YJ. Subclinical hypothyroidism and the risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Thyroid. 2018;28:1101-1110.
Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, Cappola AR, Heckbert SR, Ceresini G, Gussekloo J, den Elzen WPJ, Peeters RP, Luben R, Völzke H, Dörr M, Walsh JP, Bremner A, Iacoviello M, Macfarlane P, Heeringa J, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017;136:2100-2116.
Li Y, Liu M, Yi J, Song X, Zheng X, Liu D, Wang S, Chu C, Yang J. Exogenous hydrogen sulfide inhibits apoptosis by regulating endoplasmic reticulum stress-autophagy axis and improves myocardial reconstruction after acute myocardial infarction. Acta Biochim Biophys Sin (Shanghai). 2020;52:1325-1336.
Daliang Z, Lifang Y, Hong F, Lingling Z, Lin W, Dapeng L, Tianshu Z, Weimin L. Netrin-1 plays a role in the effect of moderate exercise on myocardial fibrosis in rats. PLoS One. 2019;14:e0199802.
Sun Y, Yao X, Zhang QJ, Zhu M, Liu ZP, Ci B, Xie Y, Carlson D, Rothermel BA, Sun Y, Levine B, Hill JA, Wolf SE, Minei JP, Zang QS. Beclin-1-dependent autophagy protects the heart during sepsis. Circulation. 2018;138:2247-2262.
Éva Sikura K, Combi Z, Potor L, Szerafin T, Hendrik Z, Méhes G, Gergely P, Whiteman M, Beke L, Fürtös I, Balla G, Balla J. Hydrogen sulfide inhibits aortic valve calcification in heart via regulating RUNX2 by NF-κB, a link between inflammation and mineralization. J Adv Res. 2020;27:165-176.
Ellmers LJ, Templeton EM, Pilbrow AP, Frampton C, Ishii I, Moore PK, Bhatia M, Richards AM, Cameron VA. Hydrogen sulfide treatment improves post-infarct remodeling and long-term cardiac function in CSE knockout and wild-type mice. Int J Mol Sci. 2020;21:4284.
Pan LL, Liu XH, Shen YQ, Wang NZ, Xu J, Wu D, Xiong QH, Deng HY, Huang GY, Zhu YZ. Inhibition of NADPH oxidase 4-related signaling by sodium hydrosulfide attenuates myocardial fibrotic response. Int J Cardiol. 2013;168:3770-3778.
Yu XH, Cui LB, Wu K, Zheng XL, Cayabyab FS, Chen ZW, Tang CK. Hydrogen sulfide as a potent cardiovascular protective agent. Clin Chim Acta. 2014;437:78-87.
Sciarretta S, Yee D, Nagarajan N, Bianchi F, Saito T, Valenti V, Tong M, Del Re DP, Vecchione C, Schirone L, Forte M, Rubattu S, Shirakabe A, Boppana VS, Volpe M, Frati G, Zhai P, Sadoshima J. Trehalose-induced activation of autophagy improves cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2018;71:1999-2010.
Dewanjee S, Vallamkondu J, Kalra RS, John A, Reddy PH, Kandimalla R. Autophagy in the diabetic heart: a potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res Rev. 2021;68:101338.
Zhang QY, Jin HF, Chen S, Chen QH, Tang CS, Du JB, Huang YQ. Hydrogen sulfide regulating myocardial structure and function by targeting cardiomyocyte autophagy. Chin Med J (Engl). 2018;131:839-844.
Lv S, Yuan P, Dong J, Lu C, Li M, Qu F, Zhu Y, Yuan Z, Zhang J. QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy. J Cell Mol Med. 2020;24:11283-11293.
Luo LF, Qin LY, Wang JX, Guan P, Wang N, Ji ES. Astragaloside IV attenuates the myocardial injury caused by adriamycin by inhibiting autophagy. Front Pharmacol. 2021;12:669782.
Margariti A, Li H, Chen T, Martin D, Vizcay-Barrena G, Alam S, Karamariti E, Xiao Q, Zampetaki A, Zhang Z, Wang W, Jiang Z, Gao C, Ma B, Chen YG, Cockerill G, Hu Y, Xu Q, Zeng L. XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation. J Biol Chem. 2013;288:859-872.
Maruyama T, Noda NN. Autophagy-regulating protease Atg4: structure, function, regulation and inhibition. J Antibiot (Tokyo). 2017;71:72-78.
Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death Differ. 2007;14:1247-1250.
Danieli A, Martens S. p62-mediated phase separation at the intersection of the ubiquitin-proteasome system and autophagy. J Cell Sci. 2018;131:jcs214304.
Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol. 2008;445:77-88.
Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542-545.
Li Y, Liu R, Wu J, Li X. Self-eating: friend or foe? The emerging role of autophagy in fibrotic diseases. Theranostics. 2020;10:7993-8017.
Guo Y, Gupte M, Umbarkar P, Singh AP, Sui JY, Force T, Lal H. Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis. J Mol Cell Cardiol. 2017;110:109-120.
Su SA, Yang D, Wu Y, Xie Y, Zhu W, Cai Z, Shen J, Fu Z, Wang Y, Jia L, Wang Y, Wang JA, Xiang M. EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-β/Smad3 signaling. Circ Res. 2017;121:617-627.
Gao H, Bo Z, Wang Q, Luo L, Zhu H, Ren Y. Salvanic acid B inhibits myocardial fibrosis through regulating TGF-β1/Smad signaling pathway. Biomed Pharmacother. 2019;110:685-691.
Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH, Yao T, Zhu YC. Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;293:H2093-H2100.
Chan EC, Peshavariya HM, Liu GS, Jiang F, Lim SY, Dusting GJ. Nox4 modulates collagen production stimulated by transforming growth factor β1 in vivo and in vitro. Biochem Biophys Res Commun. 2013;430:918-925.
Xue H, Yuan P, Ni J, Li C, Shao D, Liu J, Shen Y, Wang Z, Zhou L, Zhang W, Huang Y, Yu C, Wang R, Lu L. H2S inhibits hyperglycemia-induced intrarenal renin-angiotensin system activation via attenuation of reactive oxygen species generation. PLoS One. 2013;8:e74366.
Kumar M, Arora P, Sandhir R. Hydrogen sulfide reverses LPS-induced behavioral deficits by suppressing microglial activation and promoting M2 polarization. J Neuroimmune Pharmacol. 2021;16:483-499.
Yuan P, Xue H, Zhou L, Qu L, Li C, Wang Z, Ni J, Yu C, Yao T, Huang Y, Wang R, Lu L. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol Dial Transplant. 2011;26:2119-2126.
Lu M, Qin Q, Yao J, Sun L, Qin X. Induction of LOX by TGF-β1/Smad/AP-1 signaling aggravates rat myocardial fibrosis and heart failure. IUBMB Life. 2019;71:1729-1739.